Our Approach

Clinical research focusing on underlying causes of NASH

NASH is an increasingly common serious disease of the liver with no approved treatments. Associated with metabolic disorders like diabetes and obesity, it affects more than 15 million Americans. MGL-3196 may be the first NASH therapy in development with the potential to address the root causes of the underlying disease process in NASH.

Potential to improve treatment outcomes for FH

Both the heterozygous (HeFH) and homozygous (HoFH) forms of familial hypercholesterolemia are severe genetic disorders of lipid metabolism, typically caused by inactivating mutations in the LDL receptor, that lead to early onset cardiovascular disease.

Thyroid hormone regulation of lipid metabolism affects a wide range of interrelated health parameters, from levels of cholesterol and triglycerides in the blood to the pathological buildup of fat in the liver. Selective thyroid hormone receptor beta (THR)-β activation in the liver is an appealing target for therapeutics intended to address dysregulation of lipid metabolism.

Madrigal is advancing MGL-3196 for the treatment of NASH and familial hypercholesterolemias. The Company has multiple clinical trial initiations and data readouts for MGL-3196 planned through 2017 into 2018, including the results of Phase 2 trials in NASH and FH patients. Learn More